The backers of a fledgling northern Virginia biotech named Cary Pharmaceuticals has been out beating the bushes for $14 million in new investment funds to carry the company into the clinic. So far, about $2.6 million has been raised from family, friends, a federal grant and a manufacturing partner. Report